Fresh Tracks Therapeutics logo

Fresh Tracks TherapeuticsNASDAQ: FRTX

Profile

Sector:

Healthcare

Industry:

Biotechnology

Country:

United States

IPO:

10 March 1993

Website:

http://www.frtx.com

Next earnings report:

24 July 2024

Last dividends:

N/A

Next dividends:

N/A

Market cap

$5.61 M
-92%vs. 3y high
13%vs. sector

PE ratio

-
-vs. 3y high
-vs. sector

PB ratio

0.57
-83%vs. 3y high
29%vs. sector

PS ratio

-
-vs. 3y high
-vs. sector

Price

regular market | Fri, 05 Jul 2024 13:30:00 GMT
$0.94+$0.01(+1.08%)

Dividend

No data over the past 3 years

EPS diluted

EPS diluted target

-$0.20-

Revenue

Revenue target

$500.00 K$500.00 K

Revenue

Net income

--$1.24 M

Analysts recommendations

Total assets

Total liabilities

$11.59 M$1.66 M

Institutional Ownership

Included in screeners

Small cap companies
Top performing stocks today
Stocks with price above SMA 50
Stocks under 1$
Stocks with low beta
Analysts recommendations: buy
Growing shares outstanding

Similar companies

SunLink Health Systems logo

SunLink Health Systems (SSY)

ASLAN Pharmaceuticals Limited logo

ASLAN Pharmaceuticals Limited (ASLN)

Intelligent Bio Solutions logo

Intelligent Bio Solutions (INBS)

Aeterna Zentaris logo

Aeterna Zentaris (AEZS)

TFF Pharmaceuticals logo

TFF Pharmaceuticals (TFFP)

Sonendo logo

Sonendo (SONX)

IM Cannabis logo

IM Cannabis (IMCC)

BioCardia logo

BioCardia (BCDA)

FRTX Latest News

Fresh Tracks Therapeutics Announces Delaware Petition Filed Seeking Appointment of Custodian for Eventual Dissolution of Company
globenewswire.com17 June 2024 Sentiment: -

Company filed an answer in overall agreement with petition on June 14, 2024 and awaits a hearing date from the Delaware Chancery Court Company filed an answer in overall agreement with petition on June 14, 2024 and awaits a hearing date from the Delaware Chancery Court

What type of business is Fresh Tracks Therapeutics?

Fresh Tracks Therapeutics, Inc., a clinical-stage pharmaceutical company, engages in the development of various prescription therapeutics for the treatment of autoimmune, inflammatory, and other debilitating diseases in the United States. The company develops sofpironium bromide, which has completed Phase III clinical trials for the treatment of primary axillary hyperhidrosis; BBI-02, an oral DYRK1A inhibitor for the treatment of autoimmune and inflammatory diseases; and BBI-10, a covalent stimulator of interferon genes inhibitor for the potential treatment of autoinflammatory and rare genetic diseases, as well as next-generation kinase inhibitors. It has license and collaboration agreements with Carna Biosciences, Inc., Voronoi Inc., Bodor Laboratories, Inc. and Dr. Nicholas S. Bodor, and AnGes, Inc. The company was formerly known as Brickell Biotech, Inc. and changed its name to Fresh Tracks Therapeutics, Inc. in September 2022. Fresh Tracks Therapeutics, Inc. was founded in 2009 and is headquartered in Boulder, Colorado.

What sector is Fresh Tracks Therapeutics in?

Fresh Tracks Therapeutics is in the Healthcare sector

What industry is Fresh Tracks Therapeutics in?

Fresh Tracks Therapeutics is in the Biotechnology industry

What country is Fresh Tracks Therapeutics from?

Fresh Tracks Therapeutics is headquartered in United States

When did Fresh Tracks Therapeutics go public?

Fresh Tracks Therapeutics initial public offering (IPO) was on 10 March 1993

What is Fresh Tracks Therapeutics website?

https://www.frtx.com

Is Fresh Tracks Therapeutics in the S&P 500?

No, Fresh Tracks Therapeutics is not included in the S&P 500 index

Is Fresh Tracks Therapeutics in the NASDAQ 100?

No, Fresh Tracks Therapeutics is not included in the NASDAQ 100 index

Is Fresh Tracks Therapeutics in the Dow Jones?

No, Fresh Tracks Therapeutics is not included in the Dow Jones index

When does Fresh Tracks Therapeutics report earnings?

The next expected earnings date for Fresh Tracks Therapeutics is 24 July 2024